A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04701658 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Bamlanivimab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]